Agenus unveils colorectal cancer survey findings, highlighting the urgent need for treatment innovation

Lexington, mass.--(business wire)--agenus inc. (“agenus” or the “company”) (nasdaq: agen), an immuno-oncology company focused on innovation, today announced the results of its national colorectal cancer in focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (crc) care. colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system.
AGEN Ratings Summary
AGEN Quant Ranking